- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to compare progression-free survival (PSA progression after systemic treatment, radiologically or histologically documented progression after systemic treatment or death from any cause, whichever occurs first), using a 2x2 factorial design among treatment groups as follows: • Immediate treatment following prostatectomy [Treatment Arms: I(CHT), I(HT)] versus deferred treatment at the time of relapse [Treatment Arms: D(CHT), D(HT)] • TAXOTERE® q3w plus ELIGARD® (leuprolide acetate) [Treatment Arms: I(CHT), D(CHT)] versus ELIGARD® alone [Treatment Arms: I(HT), D(HT)]
Critère d'inclusion
- Prostate Cancer at High Risk of Relapse After Radical Prostatectomy